AU2015265620B2 - Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections - Google Patents

Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections Download PDF

Info

Publication number
AU2015265620B2
AU2015265620B2 AU2015265620A AU2015265620A AU2015265620B2 AU 2015265620 B2 AU2015265620 B2 AU 2015265620B2 AU 2015265620 A AU2015265620 A AU 2015265620A AU 2015265620 A AU2015265620 A AU 2015265620A AU 2015265620 B2 AU2015265620 B2 AU 2015265620B2
Authority
AU
Australia
Prior art keywords
spp
subject
compound
mycoplasma
uab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015265620A
Other languages
English (en)
Other versions
AU2015265620A1 (en
Inventor
Michael HUBAND
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Entasis Therapeutics Ltd
Original Assignee
Entasis Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entasis Therapeutics Ltd filed Critical Entasis Therapeutics Ltd
Publication of AU2015265620A1 publication Critical patent/AU2015265620A1/en
Application granted granted Critical
Publication of AU2015265620B2 publication Critical patent/AU2015265620B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2015265620A 2014-05-29 2015-05-27 Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections Ceased AU2015265620B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462004246P 2014-05-29 2014-05-29
US62/004,246 2014-05-29
PCT/IB2015/001585 WO2015181637A1 (en) 2014-05-29 2015-05-27 Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections

Publications (2)

Publication Number Publication Date
AU2015265620A1 AU2015265620A1 (en) 2016-11-24
AU2015265620B2 true AU2015265620B2 (en) 2020-04-09

Family

ID=54329851

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015265620A Ceased AU2015265620B2 (en) 2014-05-29 2015-05-27 Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections

Country Status (14)

Country Link
US (1) US10238661B2 (https=)
EP (1) EP3148546A1 (https=)
JP (1) JP6502387B6 (https=)
KR (1) KR20170007818A (https=)
CN (1) CN106659725A (https=)
AU (1) AU2015265620B2 (https=)
CA (1) CA2948438A1 (https=)
EA (1) EA033459B1 (https=)
IL (1) IL248838B (https=)
MX (1) MX365261B (https=)
PH (1) PH12016502271B1 (https=)
SG (2) SG10201906842WA (https=)
TW (1) TWI657818B (https=)
WO (1) WO2015181637A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109111465B (zh) * 2017-06-22 2021-01-12 中国科学院上海药物研究所 噻唑烷酮螺嘧啶三酮类化合物及制备方法和用途
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP3833665B1 (en) 2018-08-09 2023-07-19 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010043893A1 (en) * 2008-10-14 2010-04-22 Astrazeneca Ab Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
WO2014114929A1 (en) * 2013-01-23 2014-07-31 Astrazeneca Ab Compounds and methods for treating bacterial infections

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7208490B2 (en) 2002-10-07 2007-04-24 Pharmacia & Upjohn Company Llc Tricyclic tetrahydroquinoline antibacterial agents
JP2007502307A (ja) 2003-08-15 2007-02-08 アストラゼネカ アクチボラグ グルタミン酸ラセマーゼ（ｍｕｒｉ）の阻害剤としての縮合複素環
CA2606847A1 (en) 2005-05-09 2006-11-16 Warner-Lambert Company Llc Antibacterial agents
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
CL2007003332A1 (es) 2006-11-24 2008-06-20 Actelion Pharmaceuticals Ltd Compuestos derivados de heterociclos condensados; compuestos intermediarios; composicion farmaceutica; y uso en la prevencion o tratamiento de infecciones bacterianas.
US20100261719A1 (en) 2007-07-02 2010-10-14 Gregory Steven Basarab Chemical compounds
US9040528B2 (en) 2008-10-14 2015-05-26 Astrazeneca Ab Chemical compounds 542
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US8952149B2 (en) 2012-09-26 2015-02-10 Zoetis Llc Tricyclic tetrahydroquinoline antibacterial agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010043893A1 (en) * 2008-10-14 2010-04-22 Astrazeneca Ab Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
WO2014114929A1 (en) * 2013-01-23 2014-07-31 Astrazeneca Ab Compounds and methods for treating bacterial infections

Also Published As

Publication number Publication date
IL248838B (en) 2020-05-31
TW201607537A (zh) 2016-03-01
TWI657818B (zh) 2019-05-01
US20180169104A1 (en) 2018-06-21
EA201692250A1 (ru) 2017-06-30
EP3148546A1 (en) 2017-04-05
PH12016502271A1 (en) 2017-02-06
JP6502387B2 (ja) 2019-04-17
JP2017516777A (ja) 2017-06-22
IL248838A0 (en) 2017-01-31
SG10201906842WA (en) 2019-08-27
US10238661B2 (en) 2019-03-26
EA033459B1 (ru) 2019-10-31
AU2015265620A1 (en) 2016-11-24
WO2015181637A1 (en) 2015-12-03
MX365261B (es) 2019-05-27
PH12016502271B1 (en) 2017-02-06
KR20170007818A (ko) 2017-01-20
MX2016015632A (es) 2017-04-25
JP6502387B6 (ja) 2019-05-29
SG11201609404SA (en) 2016-12-29
CN106659725A (zh) 2017-05-10
CA2948438A1 (en) 2015-12-03

Similar Documents

Publication Publication Date Title
Spížek et al. Lincomycin, clindamycin and their applications
US10039777B2 (en) Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
Zhong et al. Antibiotic susceptibility of Riemerella anatipestifer field isolates
CN108658991B (zh) 3,5-二取代甲基吡唑并[1,5-a]嘧啶-7-酚盐类似物和衍生物制备方法和用途
CN103565798B (zh) 广藿香酮及其衍生物的新用途
WO2012173452A1 (ko) 진세노사이드 컴파운드 ｋ 또는 이의 유도체로 된 항균제
KR102808775B1 (ko) 결핵균 마이코박테리움 터버큘로시스(Mycobacterium tuberculosis) 감염 저항성에서의 켈리마이신의 응용
AU2015265620B2 (en) Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
RU2527769C2 (ru) Производные 5-гидроксиметилоксазолидин-2-она для лечения бактериальных кишечных заболеваний
Hartog et al. Microbiology of chronic maxillary sinusitis in adults: isolated aerobic and anaerobic bacteria and their susceptibility to twenty antibiotics
EP3065740B1 (en) Novel oxazolidinone antibacterial compound
AU2015339039B2 (en) Synergistic compositions for treating microbial infections
KR20080028459A (ko) 항균제로서의 퀴놀린 유도체
Abdu et al. Prevalence of qnr genes among multidrug resistance Staphylococcus aureus from clinical isolates
CA2281524A1 (en) Anti-microbial product
Çakan et al. Assessment of antibiotic susceptibility of Ureaplasma urealyticum from prostitutes and outpatient clinic patients using the E-test and agar dilution method
JP6084084B2 (ja) 抗菌剤、及び抗菌活性増強剤
CN113912484B (zh) 1,4,6-三羟基-8-支链-9,10-蒽醌类化合物及在制备抑菌剂中的应用
Kandimalla et al. Antibiotic sensitivity testing of Pasteurella multocida strains isolated from small ruminants
US20070281992A1 (en) Combination of gyrase b inhibitors and protein synthesis inhibitors and uses thereof
JP2010519301A (ja) 感染を処置する方法
Kulaste et al. Prevalence of microorganisms causing mastitis in dairy animals and their antibiotic resistance
Sultana et al. Clarithromycin synergism with essential and trace elements
US20050043223A1 (en) Methods for reducing or preventing transmission of nosocomial pathogens in a health care facility
CN116139131A (zh) 酚妥拉明增强红霉素对鲍曼不动杆菌的抗菌活性的应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired